Cadaver retransplants.

K Ogura; J M Cecka

Home/Archive/PubMed

PubMed · 2103169

Cadaver retransplants.

K Ogura·J M Cecka

View original source ↗Export metadata ↓

Abstract

1. Second-graft survival rates were 67% at 1 year and declined to 40% at 5 years, consistently 10% lower than those of first grafts. First- and third-graft survival rates were 77% and 58% at 1 year, respectively. The difference was apparent at 3 months. 2. Second transplants with good 1-month function had an 82% 1-year graft survival rate compared to 86% for first transplants. With good 3-month function, they had 89% 1-year survival, comparable to 91% for first transplants. 3. First-graft duration had a high prognostic value for second-graft survival. Second transplants with first-graft duration less than 3 months had 57% 1-year graft survival whereas those with more than 12 months had 75% 1-year survival. The difference was significant up to 5 years. Half-life after 1 year was 5.9 for acute responders and 5.3 for chronic responders. 4. The FCXM was a useful screening tool for second transplants. Second transplants with positive FCXM had 61% 3-month survival and those with a negative crossmatch had 82%. A positive FCXM with short first-graft duration had 48% 3-month survival and should be a contraindication for retransplantation. 5. Responder status was associated with HLA-mismatches in the first transplants. The 0-HLA-mismatched first grafts resulted in acute responders for 45-58%, which was significantly lower than 62-69% of totally HLA-mismatched first grafts. Totally HLA-mismatched first grafts were related to 3-18% lower survival for acute responders. 6. Acute responders benefited more from HLA matching than chronic responders. In acute responders, 0-HLA-A,B-mismatched grafts had a 72% 1-year graft survival rate, and 4 mis-matched had 58%. At 3 years, they had 59% and 42%, respectively. 7. HLA-DR1 recipient phenotype was associated with a 10-15% increased survival rate. DR1-positive recipients had 73% 1-year survival compared to 63% of DR1-negative recipients. 8. Never-transfused second-transplant recipients had a 59% 1-year survival rate compared to 69% for transfused. Transfusions of 1-4 units were sufficient to obtain a transfusion effect. 9. The antihuman immunoglobulin crossmatch test was associated with a 3-8% better 2-year graft survival in first and second transplants. There was no short-term beneficial effect. This assay might have detected false-negative crossmatch cases not seen by NIH or one-wash.

Explore related subjects

Antibody-Dependent Cell Cytotoxicity Blood Transfusion Cadaver Follow-Up Studies Graft Survival HLA-DR1 Antigen Histocompatibility Testing Humans Kidney Transplantation Phenotype Registries United States Journal Article

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

K Ogura, J M Cecka. 1990. Cadaver retransplants.. https://pubmed.ncbi.nlm.nih.gov/2103169/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

Granulocyte macrophage colony-stimulating factor expression in human herpetic stromal keratitis: implications for the role of neutrophils in HSK.

PURPOSE: Granulocyte macrophage colony-stimulating factor (GM-CSF) is thought to play a key role in chronic inflammatory diseases by governing the survival and function of infiltrating neutrophils. The objective of this study was to determine the putative role of GM-CSF in the pathogenesis of human herpetic stromal keratitis (HSK). METHODS: Primary human corneal fibroblast (HCF) cultures and a telomerase-immortalized human corneal epithelial (HCE) cell line representative of native HCE were stimulated with the known HSK-inducing cytokines interferon (IFN)-gamma, interleukin (IL)-1beta, and tumor necrosis factor (TNF)-alpha. Alternatively, the T-cell cytokine IL-17 was added solely or simultaneously. Human neutrophils were incubated with conditioned medium (CM) of the HCF and HCE stimulated with the aforementioned cytokines, or recombinant GM-CSF, and their viability or activation status was determined by flow cytometry. GM-CSF and IL-8 secretion levels in the CM were determined by ELISA. The antibody-dependent cellular cytotoxicity (ADCC) of neutrophils toward herpes simplex virus (HSV)-infected HCFs was determined by flow cytometry. The expression of GM-CSF was determined in HSK and control corneal buttons by real-time RT-PCR and immunohistology. RESULTS: Compared with IFN-gamma, CM of either cell type stimulated with IL-1beta, or in the case of HCE cells, stimulated with TNF-alpha or IL-17, delayed neutrophil apoptosis significantly. Only in HCFs did IL-17 exhibit a synergistic effect with TNF-alpha. The antiapoptotic activity was attributable in part to the GM-CSF secreted by the activated HCFs and HCE cells. GM-CSF stimulation of neutrophils induced their activation and the secretion of IL-8. GM-CSF did not increase significantly the ADCC reaction of neutrophils toward HSV-infected HCFs. Finally, GM-CSF was expressed in corneas of the patients with HSK but not in control subjects. CONCLUSIONS: The data suggest that GM-CSF, expressed by cornea-resident cells such as HCFs and HCE cells, may play a role in the immunopathogenesis of HSK by prolonging the survival and modulating the effector function of corneal infiltrating neutrophils.

Antibody-Dependent Cell Cytotoxicity↗

PubMed2006

Antibody-dependent cellular cytotoxicity (ADCC) is mediated by genetically modified antigen-specific human T lymphocytes.

In the context of transplantation, donor and virus-specific T-lymphocyte infusions have demonstrated the dramatic potential of T cells as immune effectors. Unfortunately, most attempts to exploit the T-cell immune system against nonviral malignancies in the syngeneic setting have been disappointing. In contrast, treatments based on monoclonal antibodies (Abs) have been clinically successful and have demonstrated the clinical relevance of several antigens as therapeutic targets and the importance of the antibody-dependent cellular cytotoxicity (ADCC) pathway. In the present study, we considered the possibility of arming specific T cells with a receptor that would enable them to mediate ADCC. After transduction with a CD16/gamma receptor gene, CD4(+) and CD8(+) cytotoxic T lymphocytes displayed stable expression of the CD16 receptor at their surface. In the absence of Ab, CD16/gamma expression did not affect the capacity of specific T lymphocytes to kill their target following "natural" T-cell receptor recognition. When tested against the autologous B-lymphoblastoid cell line (BLCL) coated with anti-CD20 mAb, the newly expressed Fc receptor enabled the T cells to kill the BLCL through ADCC. Adoptive transfer of such newly designed immune effector may be considered to increase antibody efficiency by harnessing the immune potential of T cells.

Antibody-Dependent Cell Cytotoxicity↗

PubMed2006

Porcine reproductive and respiratory syndrome virus-infected alveolar macrophages contain no detectable levels of viral proteins in their plasma membrane and are protected against antibody-dependent, complement-mediated cell lysis.

Porcine reproductive and respiratory syndrome virus (PRRSV) can evade the host immune system, which results in prolonged virus replication for several weeks to several months. To date, the mechanisms of PRRSV immune evasion have not been investigated in detail. One possible immune-evasion strategy is to avoid incorporation of viral proteins into the plasma membrane of infected cells, as this prevents recognition by virus-specific antibodies and consequent cell lysis either by the classical complement pathway or by antibody-dependent, cell-mediated cytotoxicity. In this study, viral proteins were not observed in the plasma membrane of in vitro-infected macrophages by using confocal microscopy or flow cytometry. Subsequently, the sensitivity of PRRSV-infected macrophages towards antibody-dependent, complement-mediated cell lysis (ADCML) was determined by using an ADCML assay. A non-significant percentage of PRRSV-infected cells were killed in the assay, showing that in vitro PRRSV-infected macrophages are protected against ADCML. PRRSV proteins were not detected in the plasma membrane of in vivo-infected alveolar macrophages and ADCML was also not observed. Together, these data indicate that viral proteins are not incorporated into the plasma membrane of PRRSV-infected macrophages, which makes infected cells invisible to PRRSV-specific antibodies. This absence of viral proteins on the cell surface could explain the protection against ADCML observed for in vitro and in vivo PRRSV-infected macrophages, and may play a role in virus persistence.

Antibody-Dependent Cell Cytotoxicity↗